Quest Partners LLC Purchases 634 Shares of Cencora, Inc. (NYSE:COR)

Quest Partners LLC raised its position in Cencora, Inc. (NYSE:COR) by 6.0% during the 2nd quarter, HoldingsChannel reports. The fund owned 11,263 shares of the company’s stock after buying an additional 634 shares during the quarter. Quest Partners LLC’s holdings in Cencora were worth $2,538,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Oak Thistle LLC raised its stake in shares of Cencora by 15.1% during the 2nd quarter. Oak Thistle LLC now owns 1,240 shares of the company’s stock worth $279,000 after purchasing an additional 163 shares in the last quarter. Poplar Forest Capital LLC raised its stake in shares of Cencora by 0.3% during the 2nd quarter. Poplar Forest Capital LLC now owns 120,092 shares of the company’s stock worth $27,057,000 after purchasing an additional 400 shares in the last quarter. Varma Mutual Pension Insurance Co raised its stake in shares of Cencora by 1.7% during the 2nd quarter. Varma Mutual Pension Insurance Co now owns 61,225 shares of the company’s stock worth $13,794,000 after purchasing an additional 1,025 shares in the last quarter. Hudson Edge Investment Partners Inc. bought a new stake in shares of Cencora during the 2nd quarter worth approximately $4,525,000. Finally, SRS Capital Advisors Inc. raised its stake in shares of Cencora by 6.7% during the 2nd quarter. SRS Capital Advisors Inc. now owns 3,338 shares of the company’s stock worth $752,000 after purchasing an additional 210 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. The disclosure for this sale can be found here. Insiders sold 4,450,399 shares of company stock valued at $1,070,392,799 in the last quarter. Company insiders own 15.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $234.97 on Monday. The firm has a market cap of $46.30 billion, a P/E ratio of 25.71, a price-to-earnings-growth ratio of 1.54 and a beta of 0.44. The business’s 50 day moving average is $232.44 and its 200-day moving average is $233.20. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 1-year low of $172.41 and a 1-year high of $247.66.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the business earned $2.92 EPS. Equities research analysts predict that Cencora, Inc. will post 13.61 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio is currently 22.32%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on COR shares. JPMorgan Chase & Co. upped their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Leerink Partners reiterated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. Robert W. Baird dropped their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday. StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, Wells Fargo & Company increased their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $258.13.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.